Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3-6 months. New treatment modalities are thus urgently needed. Telomerase is expressed in 85-90% of pancreas cancer, and immunogenic telomerase peptides have been characterised. A phase I/II study was conducted to investigate the safety, tolerability, and immunogenecity of telomerase peptide vaccination. Survival of the patients was also recorded. Forty-eight patients with non-resectable pancreatic cancer received intradermal injections of the telomerase peptide GV1001 at three dose levels, in combination with granulocyte-macrophage colony-stimulating factor. The treatment period was 10 weeks. Monthly booster vaccinations were offered as follow-up treatment. Immune responses were measured as delayed-type hypersensitivity skin reaction and in vitro T-cell proliferation. GV1001 was well tolerated. Immune responses were observed in 24 of 38 evaluable patients, with the highest ratio (75%) in the intermediate dose group. Twenty-seven evaluable patients completed the study. Median survival for the intermediate dose-group was 8.6 months, significantly longer for the low- (P = 0.006) and high-dose groups (P = 0.05). One-year survival for the evaluable patients in the intermediate dose group was 25%. The results demonstrate that GV1001 is immunogenic and safe to use. The survival data indicate that induction of an immune response is correlated with prolonged survival, and the vaccine may offer a new treatment option for pancreatic cancer patients, encouraging further clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“Thus a supply of relevant cytokines for polarisation of the T-cell response in the direction of a general antitumour inflammatory response, giving rise to indirect killing by CD4þ cells in HLA class II-negative tumours (Hung et al, 1998; Janssen et al, 2003) may be part of the mechanism of action.”
BackgroundThe Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Vonderheide, R. H., Hahn, W. C., Schultze, J. L., & Nadler, L. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80066-7 · Cited by 570
CD4+T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 384
Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359 · cited 3×
“Telomerase vaccination has also been demonstrated to be safe by other groups reporting clinical results from testing of hTERT mRNAtransfected dendritic cell vaccination of patients with prostate cancer (Su et al, 2005), and from vaccination of patients with c. p. m . c. p. m .”
BackgroundGjertsen, M. K., Buanes, T., Rosseland, A. R., Bakka, A., Gladhaug, I., S�reide, O., Eriksen, J. A., M�ller, M., Baksaas, I., Lothe, R. A., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1205 · Cited by 276 · cited 1×
“Based on our earlier experience with vaccination with mutant RAS peptides (Gjertsen et al, 2001), a protocol for telomerase peptide vaccination of patients with non-resectable pancreatic cancer was developed.”
BackgroundSelf-citationStorniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., & Schilsky, R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990315)85:6<1261::aid-cncr7>3.0.co;2-t · Cited by 259
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
Minev, B., Hipp, J., Firat, H., Schmidt, J. D., Langlade-Demoyen, P., & Zanetti, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070560797 · Cited by 255
Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes
Vonderheide, R. H., Domchek, S. M., Schultze, J. L., George, D. J., Hoar, K. M., Chen, D.-Y., Stephans, K. F., Masutomi, K., Loda, M., Xia, Z., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0620-3 · Cited by 254
Cited by
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 774
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Peptide Vaccine: Progress and Challenges
Li, W., Joshi, M., Singhania, S., Ramsey, K., & Murthy, A. (2014) · Vaccines · doi:10.3390/vaccines2030515 · Cited by 679
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Targeting telomeres and telomerase
De Cian, A., Lacroix, L., Douarre, C., Temime-Smaali, N., Trentesaux, C., Riou, J.-F., & Mergny, J.-L. (2008) · Biochimie · doi:10.1016/j.biochi.2007.07.011 · Cited by 572
Immunotherapy and Prevention of Pancreatic Cancer
Morrison, A. H., Byrne, K. T., & Vonderheide, R. H. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.04.001 · Cited by 464
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Biology and management of pancreatic cancer
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.103333 · Cited by 418
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70236-0 · Cited by 378
Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA
Xu, Y. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00134a · Cited by 323
Novel anticancer therapeutics targeting telomerase
Ruden, M., & Puri, N. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.007 · Cited by 310
Targeting telomerase for cancer therapeutics
Shay, J. W., & Keith, W. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604209 · Cited by 171
The Role of Telomere Biology in Cancer
Xu, L., Li, S., & Stohr, B. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164030 · Cited by 160
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Park, H.-H., Lee, K.-Y., Kim, S., Lee, J. W., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Lee, S.-H., & Koh, S.-H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.015 · Cited by 72
“GV1001 was developed as an anticancer agent and has been used for the treatment of various cancers, including advanced pancreatic cancer (Bernhardt et al., 2006; Middleton et al., 2008), melanoma (Hunger et al., 2011; Kyte et al., 2011), non-small cell lung cancer (Brunsvig et al., 2006, 2011),…”
BackgroundMethodVaccine therapy for pancreatic cancer
Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology · doi:10.4161/onci.26662 · Cited by 64
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Metadata
- Authors
- Bernhardt, S. L., Gjertsen, M. K., Trachsel, S., Møller, M., Eriksen, J. A., Meo, M., Buanes, T., & Gaudernack, G.
- Venue
- British Journal of Cancer
- Published
- 2006-10-24
- Volume
- 95
- Issue
- 11
- Pages
- 1474-1482
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2074516592
- Cited by
- 305
- References
- 30
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.